Recor Medical Responds to the American Heart Association’s (AHA) Scientific Statement on Renal Denervation for the Treatment of Hypertension
August 19, 2024 09:00 ET
|
Recor Medical
Palo Alto, CA, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) greatly appreciate the American...
CMS Approves Additional Payment for Recor Medical’s Paradise™ Ultrasound Renal Denervation System in Hospital Inpatient Cases
August 12, 2024 09:00 ET
|
Recor Medical
Palo Alto, CA, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) announced today that the Centers...
First Patients Treated in Recor Medical’s Global Paradise System US Post Approval Study (US GPS) for the Treatment of Uncontrolled Hypertension with Ultrasound Renal Denervation
July 25, 2024 10:00 ET
|
Recor Medical
Palo Alto, CA, July 25, 2024 (GLOBE NEWSWIRE) -- Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) today announced the first patients...
Recor Medical Champions Global Action on World Hypertension Day: Early Intervention and Continued Innovation Crucial in Tackling This Silent Killer Impacting Billions Worldwide
May 17, 2024 09:00 ET
|
Recor Medical
Palo Alto, CA, May 17, 2024 (GLOBE NEWSWIRE) -- Hypertension, or high blood pressure, affects nearly half of all Americans and more than one billion people worldwide. Hypertension is known as the...
Recor Medical Announces First Cases of Paradise Ultrasound Renal Denervation Therapy in the United Arab Emirates
April 18, 2024 11:00 ET
|
Recor Medical
Palo Alto, CA, April 18, 2024 (GLOBE NEWSWIRE) -- Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), announce the first commercial...